- Business Wire•20 hours agoTakeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc. today announced that data from the Phase 3 ALCANZA clinical trial evaluating ADCETRIS in patients with cutaneous T-cell lymphoma will be presented in an oral session at the 58th American Society of Hematology annual meeting on Saturday, December 3 at 2:15 p.m.
- Business Wire•22 hours agoSeattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting
Seattle Genetics, Inc. , a global biotechnology company, today highlighted phase 1b data evaluating vadastuximab talirine in combination with the frontline standard of care regimen for induction for younger patients with newly diagnosed acute myeloid leukemia in an oral presentation at the 58th American Society of Hematology Annual Meeting and Exposition taking place in San Diego, California, December ...
- Business Wire•yesterdaySeattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting
Seattle Genetics, Inc. , a global biotechnology company, today presented data from a phase 2 clinical trial evaluating ADCETRIS combination therapy in frontline diffuse large B-cell lymphoma at the 58th American Society of Hematology Annual Meeting and Exposition taking place in San Diego, California, December 3-6, 2016.
SGEN : Summary for Seattle Genetics, Inc. - Yahoo Finance
Seattle Genetics, Inc. (SGEN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||61.27 x 100|
|Ask||74.75 x 500|
|Day's Range||66.27 - 67.87|
|52 Week Range||26.02 - 75.36|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-85.19|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|